n.a. (ELN)

Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Biotech Review: Elan's Alzheimer's Drug

The promising data sent shares soaring Tuesday; here's what investors need to know now.

Tuesday's Winners & Losers: Uranium Energy

Shares rise 15.9% after the company completed the initial portion of the Goliad ISR Uranium Project.

Health Winners & Losers: Elan

Elan climbs on drug study data.

Portfolio Spotlight: SAC Capital

The hedge fund's holdings include Research In Motion and Elan.

Elan Reports Mixed Alzheimer Results

The Elan and Wyeth drug was at least partially effective in a subgroup of patients lacking a higher genetic risk for developing Alzheimer's.

Biotech Watch: Elan's Alzheimer's Drug Data

The potential market for bapineuzumab is massive. Here's how to sort the trial data when released.

Health Winners & Losers: Merck

Merck slides as UBS lowers its price target.

Biotech Notebook: Vertex, Medicines Co.

Uncertain regulation hangs on Vertex's telaprevir, The Medicines Co. remains mum on Cleviprex and a summer biotech-stock watch list.

Health Winners & Losers: Tercica

Tercica soars on news of a $663 million buyout.

Acorda Drug Improves MS Walking Speeds

A second phase III study of Fampridine-SR shows the drug improves walking in multiple sclerosis patients.

'Fast Money' Portfolios of the Week

Here are some of the stocks the 'Fast Money' crew has been talking about lately.

Myriad's Flurizan Deal Is a Hedged Bet

The way the biotech structured a licensing deal with Lundbeck for the late-stage Alzheimer's drug may protect both in a way.

Myriad Genetics Sells Flurizan Rights

Lundbeck A/S will pay as much as $350 million for European rights to the late-stage Alzheimer's drug.

Monday's Winners & Losers: Pacific Ethanol

Shares jump 60.6% after the company beats expectations.

Health Winners & Losers: Novartis

Novartis climbs on data from a kidney cancer study.

Feuerstein's Biotech-Stock Mailbag

Elan's investor meeting proves exclusive; Medarex and the FDA, and more.

Hedge Fund Manager Tells All in New Book

Fooling Some People All of the Time is a must-read for investors.

Biotech Notebook: Progenics, Wyeth

Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.

Genzyme Beats Earnings Targets

The biotech company posts first-quarter profit and revenue that just exceed expectations.

Biogen Beats Profit Expectations

Sales of the biotech company's Avonex exceed Wall Street targets in the first quarter.

Feuerstein's Biotech-Stock Mailbag

Glaxo may face a tough sell with newly approved Treximet; additional feedback on Elan, and more.

Wyeth, Elan Halt Alzheimer Drug Trial

Incidence of a skin lesion prompts the suspension of a phase II trial for their experimental vaccine ACC-001.

Wednesday's Health Winners & Losers

Pozen Pharma climbs on news of regulatory approval for migraine drug Treximet.

Biogen, Elan See Rise in Tysabri Use

Patient use of the multiple sclerosis drug makes a 25% quarter-over-quarter rise.

Feuerstein's Biotech-Stock Mailbag

The latest M&A and what it means more broadly; tapping Russia for drug approvals; the next potential insulin play and more.

Friday's Health Winners & Losers

PDL BioPharma surges on spinoff news.

Elan and Wyeth Had Ties to Study's Authors

A high-profile paper published last year failed to disclose that one of the co-authors had financial ties to the drugmakers.

Thursday's Health Winners & Losers

SGX Pharmaceuticals tanks after a drug candidate shows toxicity.

Biotech Notebook: Genentech, Exact Sciences

Avastin's approval could spark Genentech to boost earnings guidance.

Tuesday's Health Winners & Losers

Theravance and Obagi Medical plunge.